Skip to main content
RochePartnership

Roche acquires a Chinese obesity drug for 1.037 billion

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

Roche entered into a licensing agreement valued at up to 1.160 billion dollars with Rona Therapeutics for an experimental RNAi obesity treatment targeting ALK7.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Roche's headquarters in Spain. Roche reinforces its commitment to the obesity drug market with a new licensing agreement with the Chinese biotech company Rona Therapeutics. The Swiss company has signed a transaction valued at up to 1.160 billion dollars (about 1.037 billion euros) to gain access to an experimental treatment targeting obesity and other metabolic diseases. The move expands its portfolio of candidates in a therapeutic area where it competes with giants like Eli Lilly and Novo Nordisk. The agreement contemplates an upfront payment of 100 million dollars and another 1.060 billion conditional upon the achievement of development, regulatory, and commercial milestones. As announced, the maximum figure announced does not constitute an immediate outlay, but rather the potential value of the transaction if the agreed conditions are met. The new license allows Roche to incorporate into its portfolio a therapeutic approach different from the drugs that have driven the recent boom in obesity treatments. Rona's candidate is based on RNA interference (RNAi) technology, which makes it possible to reduce the expression of certain genes by silencing their messenger RNA. In this case, the experimental treatment targets the ALK7 protein, which is related to the regulation of adipose tissue. The strategy seeks to act on body fat and metabolism, with the potential to reduce...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Companies

  • Rona TherapeuticsPartnerronatherapeutics.com

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Oct 13, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/c1b19d4e-3262-0e32-f5b7-51785a7e7d82 returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "c1b19d4e-3262-0e32-f5b7-51785a7e7d82",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-13T16:05:07+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.redaccionmedica.com/empresas/industria-farmaceutica/20261013/roche-adquiere-un-farmaco-chino-contra-la-obesidad-por-millones/362022_0.html",
    "title": "Roche acquires a Chinese obesity drug for 1.037 billion - Redacción médica",
    "excerpt": "Roche's headquarters in Spain. Roche reinforces its commitment to the obesity drug market with a new licensing agreement with the Chinese biotech company Rona Therapeutics. The Swiss company has signed a transaction valued at up to 1.160 billion dollars (about 1.037 billion euros) to gain access to an experimental treatment targeting obesity and other metabolic diseases. The move expands its portfolio of candidates in a therapeutic area where it competes with giants like Eli Lilly and Novo Nordisk. The agreement contemplates an upfront payment of 100 million dollars and another 1.060 billion conditional upon the achievement of development, regulatory, and commercial milestones. As announced, the maximum figure announced does not constitute an immediate outlay, but rather the potential value of the transaction if the agreed conditions are met. The new license allows Roche to incorporate into its portfolio a therapeutic approach different from the drugs that have driven the recent boom in obesity treatments. Rona's candidate is based on RNA interference (RNAi) technology, which makes it possible to reduce the expression of certain genes by silencing their messenger RNA. In this case, the experimental treatment targets the ALK7 protein, which is related to the regulation of adipose tissue. The strategy seeks to act on body fat and metabolism, with the potential to reduce visceral...",
    "summary": "Roche entered into a licensing agreement valued at up to 1.160 billion dollars with Rona Therapeutics for an experimental RNAi obesity treatment targeting ALK7.",
    "planning": false,
    "image_url": "https://s1.redaccionmedica.com/k/imgp/cms/sanitaria2000/93511.jpg?p=f:jpeg/w:1706/h:960&h=YA4wPpFb",
    "confidence": 0.95,
    "published_at": "2026-10-13T16:05:07Z",
    "article_sentence": "The Swiss company has signed a transaction valued at up to 1.160 billion dollars (about 1.037 billion euros) to gain access to an experimental treatment targeting obesity and other metabolic diseases.",
    "related_company_name": "Rona Therapeutics",
    "related_company_domain": "ronatherapeutics.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.